Type 2 diabetes mellitus (T2DM) affects ~29.1 million individuals in the US and is associated withsignificant morbidity and mortality from both microvascular and macrovascular complications. Themicrovascular, and to a lesser extent macrovascular, complications primarily are related tohyperglycemia. Therefore, it is logical to initiate therapy early in the natural history of T2DM, at the?prediabetic? stage, with interventions that reverse specific pathophysiologic defects present in IGT andIFG.